Pierre S. Sayad has joined the IMF as Senior Vice President, Global Medical and Scientific Affairs. Pierre completed his graduate work in Molecular Physiology at Loma Linda University, School of Medicine. In 2003, he began his pharmaceutical career at Eli Lilly and Company, and held leadership roles across Commercial and Medical Affairs teams. During his ten-year tenure at Lilly, Pierre helped launch four blockbuster neuroscience medicines for various mental illnesses.
After Lilly, Pierre joined the management-consulting firm, Campbell Alliance. As a senior consultant managing projects in the Medical Affairs and Commercial practice areas, Pierre worked with clients at more than 25 pharmaceutical and biotech companies, including Pfizer, Genentech, Novartis, and GSK. In 2012, he joined Onyx Pharmaceuticals as head of Global Strategy and Operations for the Medical and Scientific Affairs Organization. He ultimately formalized and launched Onyx’s Global Strategic Partnerships program, and was heavily involved in Onyx’s transition to Amgen.
Given his role at Onyx (a subsidiary of Amgen), Pierre has been very familiar with the IMF’s Black Swan Research Initiative® and the organization’s other innovative platforms aimed at curing Myeloma. He currently works directly with the IMF President and the Chairman of the Board, and is committed to advancing myeloma treatment paradigms, ultimately improving the lives of patients.